Cartherics has an autologous CAR-T product treating ovarian cancer, entering clinical trials in 2025-26. The lead allogeneic product is expected to enter clinical trials for ovarian cancer in 2026-27. The product pipeline focuses on disruption of the tumour microenvironment enabling access and longevity of CAR-immune cell attack and establishment of memory immune surveillance. We are also developing EV products to contain any further cancer or endometriosis. We are exploring the control of severe neurological conditions with a similar approach.